These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 34697980)

  • 1. Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.
    Chatterjee B; Thakur SS
    Expert Rev Vaccines; 2022 Jan; 21(1):47-67. PubMed ID: 34697980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines against SARS-CoV-2 variants and future pandemics.
    Park T; Hwang H; Moon S; Kang SG; Song S; Kim YH; Kim H; Ko EJ; Yoon SD; Kang SM; Hwang HS
    Expert Rev Vaccines; 2022 Oct; 21(10):1363-1376. PubMed ID: 35924678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expert review on global real-world vaccine effectiveness against SARS-CoV-2.
    Chuenkitmongkol S; Solante R; Burhan E; Chariyalertsak S; Chiu NC; Do-Van D; Husin M; Hwang KP; Kiertiburanakul S; Kulkarni PS; Lee PI; Lobo RC; Nghia CH; Ong-Lim A; Sivasampu S; Suah JL; Tok PSK; Thwaites G;
    Expert Rev Vaccines; 2022 Sep; 21(9):1255-1268. PubMed ID: 35748494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidly Evolving SARS-CoV-2: A Brief Review Regarding the Variants and their Effects on Vaccine Efficacies.
    Nawaz S; Janiad S; Fatima A; Saleem M; Fatima U; Ali A
    Infect Disord Drug Targets; 2024; 24(4):58-66. PubMed ID: 38178666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts.
    Rashedi R; Samieefar N; Masoumi N; Mohseni S; Rezaei N
    J Med Virol; 2022 Apr; 94(4):1294-1299. PubMed ID: 34796525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.
    Li Q; Wang J; Tang Y; Lu H
    Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case-control study with SARS-CoV-2 genetic sequencing.
    Bijukchhe SM; O'Reilly PJ; Theiss-Nyland K; Gurung M; Pokhrel B; Kelly S; Acharya S; Maharjan S; Shrestha A; Pandey B; Lama M; Shrestha I; Voysey M; Eordogh A; Shrestha S; Feng ES; Li G; Shah G; Pollard AJ; Shrestha S
    BMJ Open; 2023 Apr; 13(4):e068334. PubMed ID: 37072367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico.
    Galán-Huerta KA; Flores-Treviño S; Salas-Treviño D; Bocanegra-Ibarias P; Rivas-Estilla AM; Pérez-Alba E; Lozano-Sepúlveda SA; Arellanos-Soto D; Camacho-Ortiz A
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
    Noor R
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.
    Chavda VP; Yao Q; Vora LK; Apostolopoulos V; Patel CA; Bezbaruah R; Patel AB; Chen ZS
    Front Immunol; 2022; 13():961198. PubMed ID: 36263030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.
    Simões RSQ; Rodríguez-Lázaro D
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection.
    Chi WY; Li YD; Huang HC; Chan TEH; Chow SY; Su JH; Ferrall L; Hung CF; Wu TC
    J Biomed Sci; 2022 Oct; 29(1):82. PubMed ID: 36243868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The way of SARS-CoV-2 vaccine development: success and challenges.
    Dong Y; Dai T; Wang B; Zhang L; Zeng LH; Huang J; Yan H; Zhang L; Zhou F
    Signal Transduct Target Ther; 2021 Nov; 6(1):387. PubMed ID: 34753918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study.
    Li R; Li Y; Zou Z; Liu Y; Li X; Zhuang G; Shen M; Zhang L
    Front Public Health; 2021; 9():801763. PubMed ID: 35083192
    [No Abstract]   [Full Text] [Related]  

  • 19. An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.
    Kantarcioglu B; Iqbal O; Lewis J; Carter CA; Singh M; Lievano F; Ligocki M; Jeske W; Adiguzel C; Gerotziafas GT; Fareed J
    Clin Appl Thromb Hemost; 2022; 28():10760296211056648. PubMed ID: 35167393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of COVID-19 vaccines among children and adolescents against SARS-CoV-2 variants: a meta-analysis.
    Lan Z; Yan J; Yang Y; Tang Z; Guo X; Wu Z; Jin Q
    Eur J Pediatr; 2023 Dec; 182(12):5235-5244. PubMed ID: 37768334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.